---
schema_version: "secwatch.filing_event.v1"
accession: "0000805928-22-000110"
form_type: "8-K"
ticker: "AXGN"
cik: "0000805928"
company_name: "Axogen, Inc."
filed_at: "2022-10-31T23:59:59+00:00"
generated_at: "2026-06-22T22:08:27.380370+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Axogen appoints Adrian Tyndall to board; founding director Mark Gold retires Dec 13

## Summary
- Founding director Dr. Mark Gold resigns effective Dec 13, 2022; no dispute cited.
- Dr. Adrian Tyndall appointed to board effective Dec 13; will serve on Quality, Compliance & Portfolio Committee.
- Tyndall is Exec VP for Health Affairs & Dean of Morehouse School of Medicine; former UF College of Medicine interim dean.
- Tyndall receives standard director compensation: $10k quarterly cash retainer, $1.25k committee retainer, $275k initial option grant vesting over 3 years.

## SEC filing metadata
- accession: 0000805928-22-000110
- form_type: 8-K
- ticker: AXGN
- cik: 0000805928
- company_name: Axogen, Inc.
- filed_at: 2022-10-31T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/805928/000080592822000110/0000805928-22-000110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/805928/000080592822000110/axgn-20221025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000805928-22-000110
- JSON: https://secwatch.observer/filing/0000805928-22-000110.json
- Plain text: https://secwatch.observer/filing/0000805928-22-000110.txt

## Key facts
- Executive change
  Mark Gold resigned as Director at Axogen, Inc..
  - Action: resigned
  - Role: Director
  source text: On October 24, 2022, Mark Gold, M.D. notified Axogen, Inc. (the “Company”) of his decision to resign as a member of the Company’s Board of Directors (the “Board”), including as a member of the Quality, Compliance and Portfolio Management Committee, effective as of 3:00 PM EST on Tuesday, December 13, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/805928/000080592822000110/0000805928-22-000110-index.htm
- Executive change
  Joseph Adrian Tyndall was appointed as Director at Axogen, Inc..
  - Action: appointed
  - Role: Director
  source text: On October 25 2022, the Company's Board appointed Joseph Adrian Tyndall, M. D. as a new director to fill the vacant directorship on the Board, effective December 13, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/805928/000080592822000110/0000805928-22-000110-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.